Panacea Biotec, a leading biotechnology company in India, has received a long-term loan commitment of up to $20 million from the U.S. International Development Finance Corporation (DFC). The funding will support Panacea Biotec’s capacity-expansion project for its hexavalent vaccine, EasySix.
Launched in India in 2017, EasySix is the world’s first fully liquid hexavalent vaccine combining whole-cell pertussis (wP) and inactivated polio (IPV). This vaccine simplifies immunization by reducing the number of vaccination sessions compared to the traditional pentavalent and standalone IPV vaccines.
With growing global demand, especially from UNICEF and Gavi-supported countries, Panacea Biotec is expanding its manufacturing capabilities to meet future needs. The DFC loan will accelerate the expansion, ensuring that Panacea Biotec can supply this life-saving vaccine to U.N. agencies for childhood immunization worldwide.